297 related articles for article (PubMed ID: 25482134)
1. CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis.
Finazzi MC; Carobbio A; Cervantes F; Isola IM; Vannucchi AM; Guglielmelli P; Rambaldi A; Finazzi G; Barosi G; Barbui T
Leukemia; 2015 May; 29(5):1209-10. PubMed ID: 25482134
[No Abstract] [Full Text] [Related]
2. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
3. Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.
Asp J; Andréasson B; Hansson U; Wasslavik C; Abelsson J; Johansson P; Palmqvist L
Haematologica; 2016 Apr; 101(4):e129-32. PubMed ID: 26768689
[No Abstract] [Full Text] [Related]
4. Essential thrombocythaemia with mutation in
Alvarez-Larran A; Martínez D; Arenillas L; Rubio A; Arellano-Rodrigo E; Hernández Boluda JC; Papaleo N; Caballero G; Martínez C; Ferrer-Marín F; Mata MI; Pérez-Encinas M; Durán MA; Alonso JM; Carreño-Tarragona G; Alonso JM; Noya S; Magro E; Pérez R; López-Guerra M; Pastor-Galán I; Cervantes F; Besses C; Colomo L; Rozman M
J Clin Pathol; 2018 Nov; 71(11):975-980. PubMed ID: 29934356
[TBL] [Abstract][Full Text] [Related]
5. JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
Kim BH; Cho YU; Bae MH; Jang S; Seo EJ; Chi HS; Choi Y; Kim DY; Lee JH; Lee JH; Lee KH; Park YM; Lee JK; Park CJ
J Korean Med Sci; 2015 Jul; 30(7):882-8. PubMed ID: 26130950
[TBL] [Abstract][Full Text] [Related]
6. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
[TBL] [Abstract][Full Text] [Related]
7. Calreticulin mutation profile in Indian patients with primary myelofibrosis.
Sazawal S; Singh N; Mahapatra M; Saxena R
Hematology; 2015 Dec; 20(10):567-70. PubMed ID: 25959795
[TBL] [Abstract][Full Text] [Related]
8. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
Tefferi A; Guglielmelli P; Larson DR; Finke C; Wassie EA; Pieri L; Gangat N; Fjerza R; Belachew AA; Lasho TL; Ketterling RP; Hanson CA; Rambaldi A; Finazzi G; Thiele J; Barbui T; Pardanani A; Vannucchi AM
Blood; 2014 Oct; 124(16):2507-13; quiz 2615. PubMed ID: 25037629
[TBL] [Abstract][Full Text] [Related]
9. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis.
Rumi E; Pietra D; Pascutto C; Guglielmelli P; Martínez-Trillos A; Casetti I; Colomer D; Pieri L; Pratcorona M; Rotunno G; Sant'Antonio E; Bellini M; Cavalloni C; Mannarelli C; Milanesi C; Boveri E; Ferretti V; Astori C; Rosti V; Cervantes F; Barosi G; Vannucchi AM; Cazzola M;
Blood; 2014 Aug; 124(7):1062-9. PubMed ID: 24986690
[TBL] [Abstract][Full Text] [Related]
10. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.
Elala YC; Lasho TL; Gangat N; Finke C; Barraco D; Haider M; Abou Hussein AK; Hanson CA; Ketterling RP; Pardanani A; Tefferi A
Am J Hematol; 2016 May; 91(5):503-6. PubMed ID: 26890983
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease].
Melikyan AL; Subortseva IN; Sudarikov AB; Kovrigina AM; Gilyazitdinova EA; Kolosheinova TI; Abdullaev AO; Treglazova SA
Ter Arkh; 2017; 89(7):4-9. PubMed ID: 28766534
[TBL] [Abstract][Full Text] [Related]
12. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.
Palandri F; Latagliata R; Polverelli N; Tieghi A; Crugnola M; Martino B; Perricone M; Breccia M; Ottaviani E; Testoni N; Merli F; Aversa F; Alimena G; Cavo M; Martinelli G; Catani L; Baccarani M; Vianelli N
Leukemia; 2015 Jun; 29(6):1344-9. PubMed ID: 25801912
[TBL] [Abstract][Full Text] [Related]
13. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.
Tefferi A; Lasho TL; Finke CM; Knudson RA; Ketterling R; Hanson CH; Maffioli M; Caramazza D; Passamonti F; Pardanani A
Leukemia; 2014 Jul; 28(7):1472-7. PubMed ID: 24402162
[TBL] [Abstract][Full Text] [Related]
14. A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients.
Zaidi U; Sufaida G; Rashid M; Kaleem B; Maqsood S; Mukry SN; Khan RZA; Munzir S; Borhany M; Shamsi TS
BMC Cancer; 2020 Mar; 20(1):205. PubMed ID: 32164591
[TBL] [Abstract][Full Text] [Related]
15. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
[TBL] [Abstract][Full Text] [Related]
16. Correlation of mutation status and morphological changes in essential thrombocythaemia and myelofibrosis.
Chua CC; Omerod A; Wight J; Juneja S; Zantomio D
Pathology; 2018 Oct; 50(6):671-674. PubMed ID: 30097170
[No Abstract] [Full Text] [Related]
17. Life, genes, and death in Ph- MPNs.
Silver RT
Blood; 2014 Oct; 124(16):2471-2. PubMed ID: 25323682
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.
Mela Osorio MJ; Ferrari L; Goette NP; Gutierrez MI; Glembotsky AC; Maldonado AC; Lev PR; Alvarez C; Korin L; Marta RF; Molinas FC; Heller PG
Eur J Haematol; 2016 Apr; 96(4):435-42. PubMed ID: 26119186
[TBL] [Abstract][Full Text] [Related]
19. Co-occurrence of type I CALR and two MPL mutations in patient with primary myelofibrosis.
Tashkandi H; Moore EM; Tomlinson B; Goebel T; Sadri N
Ann Hematol; 2017 Aug; 96(8):1417-1418. PubMed ID: 28502030
[No Abstract] [Full Text] [Related]
20. Identification of MPL W515L/K mutations in patients with primary myelofibrosis and essential thrombocythaemia by allele-specific polymerase chain reaction.
Daly S; Conneally E; Langabeer SE
Acta Haematol; 2009; 121(4):221-2. PubMed ID: 19521067
[No Abstract] [Full Text] [Related]
[Next] [New Search]